Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | NNMT | P40261 | 3/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6057013 | 0.81 | POLB (0.37) | KCNJ1NNMTSIRT6ERN1 | |
| SCHEMBL29955754 | 0.81 | POLB (0.37) | KCNJ1NNMTSIRT6ERN1 | |
| SCHEMBL29953478 | 0.79 | SIRT6 (0.33) | KCNJ1SIRT6ERN1 | |
| SCHEMBL30852204 | 0.79 | SIRT6 (0.37) | KCNJ1NNMTSIRT6ERN1 | |
| SCHEMBL6056942 | 0.79 | SIRT6 (0.33) | KCNJ1SIRT6ERN1 | |
| SCHEMBL22090180 | 0.76 | KCNJ1 (0.46) | KCNJ1KDM4E | |
| SCHEMBL23028344 | 0.75 | KCNJ1 (0.49) | KCNJ1KDM4E | |
| SCHEMBL29956450 | 0.75 | KCNJ1 (0.49) | KCNJ1KDM4E | |
| SCHEMBL31214278 | 0.75 | NPSR1 (0.44) | NNMTSIRT6KDM4E | |
| SCHEMBL17431082 | 0.74 | NNMT (0.38) | NNMTSIRT6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | AMGEN INC (US) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252059-A1 | BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF | BACE1, BACE2, APP | KCNJ1 3135/4885NNMT 610/4885SIRT6 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.